News & Updates

Vaccination with either BNT162b2 or mRNA-1273 results in a comparable risk of breakthrough COVID-19 infection among patients with systemic autoimmune rheumatic diseases (SARDs) using immunomodulatory medication, a study has shown.

Treatment with hydrochlorothiazide (HCT) contributes to a lower all-cancer risk and a slightly higher skin cancer risk compared with alternative diuretics, reports a study involving a German population.

For children and adolescents who have been previously exposed to SARS-CoV-2 infection, vaccination with BNT162b2 appears to provide additional protection against omicron BA.4 or BA.5 and XBB variant infections, according to a study from Singapore.

Among patients with unresectable hepatocellular carcinoma (HCC) scheduled to receive standard combination therapy with atezolizumab plus bevacizumab, those with high levels of serum osteopontin at baseline are likely to have poor response to treatment, as shown in a study.

Uncertainty weighs heavily on managing tuberculosis (TB) infection in children, with multi-level factors influencing the decision-making regarding testing and treatment.

The direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) was effective and safe for the treatment of chronic hepatitis C virus (HCV) infection in individuals aged 6–18 years, the PANDAA-PED study has shown.

Both the 2-dose and 3-dose vaccination schedules of the four-component meningococcal serogroup B vaccine (4CMenB) appear to provide protection against a panel epidemiologically relevant strains in adolescents and young adults, according to a phase III study presented at ESPID 2023.